Celularity Inc. Deferred Offering Costs
Celularity Inc. (CELU) had Deferred Offering Costs of $16.47 million as of 2021-06-30, per its 10-Q filed 2021-08-19.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2021-08-19
- 2021-06-30: Deferred Offering Costs $16.47M.
- 2021-03-31: Deferred Offering Costs $16.47M.
- 2020-12-31: Deferred Offering Costs $16.47M.
- 2020-09-30: Deferred Offering Costs $16.47M.
| Period end | Deferred Offering Costs |
|---|---|
| 2021-06-30 | $16.47M 10-Q · filed 2021-08-19 |
| 2021-03-31 | $16.47M 10-Q · filed 2021-05-24 |
| 2020-12-31 | $16.47M 10-K/A · filed 2021-05-24 |
| 2020-09-30 | $16.47M 10-Q · filed 2020-11-16 |
| 2020-06-30 | $16.47M 10-Q · filed 2020-08-13 |
| 2020-03-31 | $16.47M 10-Q · filed 2020-05-15 |
| 2019-12-31 | $16.47M 10-K · filed 2020-03-24 |
| 2019-09-30 | $16.47M 10-Q · filed 2019-11-13 |
| 2019-06-30 | $16.47M 10-Q · filed 2019-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |